Ganga Pharmaceuticals (539680) H2 17/18 earnings summary

Executive summary

• FY18 revenue from operations was ₹305.24 lakh and profit after tax was ₹9.40 lakh, versus ₹301.04 lakh and ₹7.42 lakh in FY17; operations remained focused on Ayurvedic pharmaceuticals and allied products.

• The business continued new product introductions, distribution-network development and consumer-awareness efforts; no change in business nature was reported.

Financial highlights

• Revenue from operations rose to ₹30.53 million from ₹30.10 million; total revenue was ₹31.99 million versus ₹31.67 million.

• Profit before tax was ₹1.27 million versus ₹1.06 million; profit after tax was ₹0.94 million versus ₹0.74 million.

• Employee benefits expense increased to ₹4.36 million from ₹3.33 million, including directors’ remuneration of ₹4.18 million versus ₹3.27 million.

Outlook and guidance

• Long-term priorities include scaling authentic Ayurveda, customer satisfaction, domestic-market expansion, distribution investment and products targeting diabetes, inflammation and obesity.

• Some new formulations underwent human clinical trials; plans also emphasized R&D, product innovation and developing patented products.

• Outlook cited potential support from proposed AYUSH clusters, pluralistic healthcare initiatives and 100% FDI in the AYUSH sector.